

A new target for neuroblastoma

15 February 2018

Neuroblastoma, a cancer that starts in nerve tissue outside of the brain, is the third most common cancer in children and accounts for about 15 percent of pediatric cancer-related deaths.

Sirtuins (SIRT6), a family of proteins with roles in metabolism, aging and genomic stability, have been linked to various cancers, but their role in neuroblastoma has not been explored.

Dai Chung, MD, and colleagues found that a non-specific SIRT6 inhibitor reduced the growth rate of cultured neuroblastoma cells and induced the formation of neurite-like structures consistent with [neuronal differentiation](#) (maturation). Using a genetic strategy to knock down specific SIRT6s, they discovered that SIRT6 promotes neuroblastoma cell growth and represses differentiation. SIRT6 expression was reduced in differentiated human neuroblastoma samples and in cultured neuroblastoma cells that were induced to differentiate using retinoic acid.

The findings, reported in the February issue of *Anticancer Research*, highlight the oncogenic properties of SIRT6 in neuroblastoma and suggest SIRT6 as a target for new therapeutics for [neuroblastoma](#).

More information: Inhibition of Sirtuin 6 Induces Neuroblastoma Differentiation. *Anticancer Res* February 2018 38 (2) 647-654.
ar.iijournals.org/content/38/2/647.abstract

Provided by Vanderbilt University

APA citation: A new target for neuroblastoma (2018, February 15) retrieved 5 June 2021 from <https://medicalxpress.com/news/2018-02-neuroblastoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.